The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 Mar 2017 09:23

RNS Number : 6032A
Faron Pharmaceuticals Oy
27 March 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Faron Pharmaceuticals Oy

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund

 

4. Full name of shareholder(s)  (if different from 3.):iv

BNY Mellon Trust and Depositary as Trustee to the City Financial Absolute Equity Fund

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

21 March 2017

6. Date on which issuer notified:

24 March 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

FI4000153309

 

1,440,530

1,440,530

1,140,530

1,140,530

0

4.11%

0

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,140,530

4.11%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

The voting rights are managed and controlled by City Financial Investment Company Limited, Investment manager and ACD to the City Financial Absolute Equity Fund.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Ben Ellenbogen

15. Contact telephone number:

0207 451 9600

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLMMGZFRNKGNZG
Date   Source Headline
5th Mar 201810:12 amRNSHolding(s) in Company
2nd Mar 20181:30 pmRNSHolding(s) in Company
2nd Mar 20181:25 pmRNSHolding(s) in Company
1st Mar 201812:42 pmRNSHoldings in Company
1st Mar 201812:41 pmRNSHoldings in Company
26th Feb 20181:37 pmRNSIssue of Equity
21st Feb 20183:31 pmRNSResults of Placing & Issue of Equity
21st Feb 20187:00 amRNSFaron hosts R&D Day today in London
16th Feb 20187:00 amRNSProposed Placing to raise up to £15m
5th Feb 20187:00 amRNSSecond Traumakine manufacturing site established
1st Feb 20187:00 amRNSFaron Announces Clevegen Grant of European Patent
29th Jan 20187:00 amRNSFDA grants Fast Track Designation for Traumakine®
24th Jan 20187:00 amRNSFDA approval of Faron's Traumakine® IND
19th Dec 20177:00 amRNSINFORAAA trial receives recommendation from IDMC
14th Dec 20177:00 amRNSFaron announces R&D Day in February 2018
11th Dec 20177:32 amRNSRecruitment completed in Traumakine INTEREST Trial
6th Dec 20176:06 pmRNSHolding(s) in Company
1st Dec 20172:55 pmRNSHoldings in Company
1st Dec 20177:01 amRNSAppointment of Chief Commercial Officer
24th Nov 201710:23 amRNSHolding(s) in Company
21st Nov 20177:00 amRNSGrant of options
20th Nov 20177:00 amRNSChange of Adviser
16th Oct 20179:00 amRNSHolding(s) in Company
13th Oct 20179:00 amRNSDirector/PDMR Shareholding
11th Oct 20172:00 pmRNSIssue of Equity & PDMR Shareholding
9th Oct 20174:30 pmRNSResult of Placing & Subscription & Issue of Equity
5th Oct 20177:00 amRNSProposed Placing and Subscription
2nd Oct 20177:00 amRNSTraumakine Receives PIM Designation from MHRA
11th Sep 20173:19 pmRNSDirectors Dealings
6th Sep 20177:00 amRNSInterim Results
4th Sep 20177:00 amRNSFDA advises Faron to proceed directly to BLA
4th Aug 20177:00 amRNSUpdate on INTEREST Phase III Study from IDMC
28th Jul 20179:34 amRNSHolding(s) in Company
10th Jul 20174:51 pmRNSHolding(s) in Company
10th Jul 20177:00 amRNSNotice of Results
16th Jun 20172:43 pmRNSDirector/PDMR Shareholding
1st Jun 20177:00 amRNSExercise of Warrants and Options
30th May 20172:06 pmRNSHoldings in Company
22nd May 201711:31 amRNSDirector/PDMR Shareholding
22nd May 20177:00 amRNSDirector/PDMR Shareholding
18th May 20179:20 amRNSDirector/PDMR Shareholding
16th May 201712:00 pmRNSResult of AGM
8th May 20174:40 pmRNSSecond Price Monitoring Extn
8th May 20174:35 pmRNSPrice Monitoring Extension
8th May 20177:00 amRNSUpdate on INTEREST Phase III Study from IDMC
27th Apr 20175:57 pmRNSExercise of Warrants
26th Apr 201712:32 pmRNSDirector's dealings
21st Apr 20175:56 pmRNSDirector/PDMR Shareholding
19th Apr 20177:00 amRNSNotice of Annual General Meeting
19th Apr 20177:00 amRNSProposed Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.